News

The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma,

As part of the deal, the two parties will jointly carry out the clinical proof of concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for

As part of the deal, DURECT will receive an upfront fee of $2m in cash from Santen as well as reverie contingent cash payments upon the achievement of

Black fungus is known to benefit health issues associated with the lungs, stomach and liver in the Eastern culture. It is rich in iron, protein, vitamins, polysaccharide, fiber,

Following approval, rIX-FP will provide people with hemophilia B and their physicians a long-acting treatment option with dosing intervals up to 14 days. The BLA is based on

In the UK, venous thrombosis or blood clotting is a major cause of death and for those patients that survive PE and DVT, there can be long term

The approval was based on demonstration of improved progression-free survival (PFS) in a 96-week Phase III trial called CLARINET. The multi-center, international, randomized, double-blind, placebo-controlled trial enrolled a

Backed by funding of €15.1m from the European Commission (EC), the new consortium includes GSK and research partners from University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne

Signifor LAR is a somatostatin analog (SSA) administered intramuscularly once-monthly, which exerts its pharmacological activity through binding to somatostatin receptors (SSTRs). Novartis Oncology president Bruno Strigini said: "The